[Treatment of estrogen-resistant forms of cancer of the prostate].
D000311:Adrenal Glands / Q000503:physiopathology; D000315:Adrenalectomy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002369:Castration; D003452:Cryosurgery; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007016:Hypophysectomy; D008297:Male; D009639:Norethandrolone / Q000627:therapeutic use; D010902:Pituitary Gland / Q000378:metabolism / Q000503:physiopathology; D011388:Prolactin / Q000494:pharmacology; D011467:Prostate / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D045165:Testosterone Congeners / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004967:Estrogens; D045165:Testosterone Congeners; D011388:Prolactin; D005640:Follicle Stimulating Hormone; D009639:Norethandrolone
Lechenie estrogenorezistentnykh form raka predstatel'noĭ zhelezy